---
category: news
title: "myCare-023 Finds Cellworks Personalized Biosimulation a Stronger Predictor of Therapy Response for AML Patients than Physician Prescribed Treatment"
excerpt: "Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-023 clinical trial, which found that the Cellworks Biosimulation Platform with its Therapy Response Index (TRI) reliably predicts complete response (CR) and overall survival (OS) for individual Acute Myeloid Leukemia (AML) patients beyond physician prescribed treatment."
publishedDateTime: 2021-12-14T13:09:00Z
originalUrl: "https://www.tmcnet.com/usubmit/-mycare-023-finds-cellworks-personalized-biosimulation-stronger-predictor-/2021/12/14/9510686.htm"
webUrl: "https://www.tmcnet.com/usubmit/-mycare-023-finds-cellworks-personalized-biosimulation-stronger-predictor-/2021/12/14/9510686.htm"
type: article

provider:
  name: TMCnet
  domain: tmcnet.com

topics:
  - AI in Healthcare
  - AI

secured: "VSHwGFbO7kZiANhPIEh9WqPsbKIyhvaJJiMP//SfDolFiEpjn9hMaDSR7cJYC/RZypwDcLgtyIDK5xz33MLdL6mxxUjM3SWw43wIbPT2ldvkZBB7JuS0am2zE2Gy1Y+dSCtNcOH2WoTnCmCJVoHGYb5cSTVne28CFdJ7TdE/ysuGdlc5HwxQmlpp9ykjBGYpMbVnbAMjpX3Zw08X3/oMdUTdugEEDEmZa/7Rb6T7BfrMtD9HWCrmXESKYY9WE0B+88lamrFUJb+JIaHs8quU4jtq6mQ53zaoEBp0UnHvYbflcARkPxinWjPCxGRZvM3C1CRFnc+sKql23I7/kuhU4ixUI0k2VLpRrEHZvVHQzXw=;IxM1C9cSuZl53M+tAXBhLg=="
---

